Healthcare / BiotechnologyNasdaqCM
$0.40
-0.00 (-0.25%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-9.4M · quality 52.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-188.9%
↓Gross Margin
64.8%
↑Debt/Equity
0.47
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+99.4%
FCF CAGR
—
FCF margin
-398.4%
FCF / Net income
0.82x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.4M · net income $-11.5M · FCF $-9.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.4M | $2.4M | $515000.00 | $11.0M | $299000.00 |
| Net Income | $-11.5M | $-11.5M | $-16.6M | $-7.0M | $-16.9M |
| EBITDA | $-10.6M | $-10.6M | $-16.2M | $-6.4M | $-16.0M |
| EPS | -0.94 | -0.94 | -1.45 | -0.62 | -1.53 |
| Gross Margin | 64.8% | 64.8% | -215.5% | 81.8% | -33.8% |
| Operating Margin | -484.3% | -484.3% | -3349.7% | -68.5% | -5718.1% |
| Net Margin | -484.6% | -484.6% | -3225.0% | -64.0% | -5660.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.47 | 0.47 | 0.23 | 0.11 | 0.09 |
| Current Ratio | 2.52 | 2.52 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-9.4M | $-9.4M | $-14.6M | $-3.7M | $-15.0M |
| Returns | |||||
| ROE | -188.9% | -188.9% | -123.3% | -24.8% | -52.4% |
| Valuation | |||||
| P/B | 0.80 | 0.80 | 3.59 | 2.47 | 2.99 |
| Growth & Yield | |||||
| Revenue Growth | 360.4% | 360.4% | -95.3% | 3565.2% | — |
| EPS Growth | 35.2% | 35.2% | -133.9% | 59.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-87.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.45 → -0.94
Residual
-87.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.